Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Sara K. Silbert, Cynthia Harrison, D. Nathan Biery, Alexandra Semchenkova, Elena Zerkalenkova, Anna Alonso-Saladrigues, Kaylyn Utley, Ibrahim Aldoss, Liping Zhao, Sneha Fernandes, Jeremy D. Rubinstein, Naomi Torres Carapia, Bill H. Chang, Anant Vatsayan, Barbara De Moerloose, Holly L. Pacenta, Dennis John Kuo, Gabriele Escherich, Benjamin J. Lee, Michele S. Redell, Mandi R. Fitzjohn, Daniel P. Larson, Nicolas Duployez, Raymund S. Cuevo, Rui Rochelle He, David Dickens, Firas El Chaer, Kelly Reed, Matthias Wolfl, Sunil S. Raikar, Süreyya Savaşan, Latika Puri, Zhubin J. Gahvari, Aimee C. Talleur, Hisham Abdel-Azim, Aghiad Chamdin, Marlie R.M. Provost, Vanessa A. Fabrizio, Kerstin Mezger, Alexandra McLean Stevens, Emily M. Hsieh, Hao-Wei Wang, Constance M. Yuan, Ulrich A. Duffner, Jing Pan, Sara Ghorashian, Susana Rives, Chloe Hoang, Kara L. Davis, Elad Jacoby, Alexander Popov, Adam Lamble, Nirali N. Shah

Blood (2023) 142 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2023-182293

Published: 2023

Journal Articles

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Blood (2023) 142 (Supplement 1): 771.

https://doi.org/10.1182/blood-2023-179667

Published: 2023

Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Blood (2023) 142 (Supplement 1): 337.

https://doi.org/10.1182/blood-2023-181811

Published: 2023

Journal Articles

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Katherine Weissler, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Hao-Wei Wang, Constance M. Yuan, David F. Stroncek, Steven Highfill, Micaela Ganadan, Rashmika Patel, Steven A Rosenberg, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 7433–7434.

https://doi.org/10.1182/blood-2022-159156

Published: 2022

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, Tyler Lowe, David F. Stroncek, Steven Highfill, Rashmika Patel, Micaela Ganadan, Steven A Rosenberg, James N. Kochenderfer

Blood (2021) 138 (Supplement 1): 3837.

https://doi.org/10.1182/blood-2021-152688

Published: 2021

Journal Articles

CD22 low /Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

Ernesto Diaz-Flores, Astrid Wintering, Kenichi Ishiyama, Stanley Tamaki, Courtney Tamaki, Josh Fandel, Lingyun Ji, Brent Wood, Constance M. Yuan, Nirali N. Shah, Maureen M. O'Brien, Mignon L. Loh

Blood (2021) 138 (Supplement 1): 614.

https://doi.org/10.1182/blood-2021-149037

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Ralph Mangusan, DNP, CRNP, Jomy George, PharmD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Mark Roth, MD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Vickie Ann Marshall, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-137188

Published: 2020

Journal Articles

Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate

Kathryn Lurain, Thomas S. Uldrick, Ramya Ramaswami, Mark N. Polizzotto, Priscila H. Goncalves, Anaida Widell, Seth M. Steinberg, Elaine S. Jaffe, Stefania Pittaluga, Hao-Wei Wang, Constance M. Yuan, Mary Anne Tamula, Staci Martin, Pamela L. Wolters, Jomy George, Richard F. Little, Robert Yarchoan

Blood (2020) 136 (19): 2229–2232.

https://doi.org/10.1182/blood.2020006048

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-136148

Published: 2020

Journal Articles

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-138839

Published: 2020

Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Blood (2020) 136 (1): 93–105.

https://doi.org/10.1182/blood.2019003715

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Lekha Mikkilineni, MD, Elisabet E. Manasanch, MD, Norris Lam, BS, Danielle Vanasse, BS, Jennifer N. Brudno, MD, Irina Maric, MD MSci, Jeremy J. Rose, MS, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, David F. Stroncek, MD, Jennifer Mann, CRNP, Micaela Ganadan, BSN, RN, Rashmika Patel, Nathan Trinklein, PhD, Ben Buelow, MD PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2019) 134 (Supplement_1): 3230.

https://doi.org/10.1182/blood-2019-129088

Published: 2019

Journal Articles

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Kathryn Lurain, MD MPH, Thomas S. Uldrick, MD MS, Priscila H. Goncalves, MD, Ramya Ramaswami, MBBS, MPH, Mark N. Polizzotto, Anaida Widell, Seth M. Steinberg, PhD, Elaine S. Jaffe, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Richard F. Little, MD MPH, Robert Yarchoan, MD

Blood (2018) 132 (Supplement 1): 2963.

https://doi.org/10.1182/blood-2018-99-112169

Published: 2018

NARROW

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

CD22 low /Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only